Adherium 将来の成長

Future 基準チェック /66

Adherium利益と収益がそれぞれ年間73.7%と86.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に68% 84.3%なると予測されています。

主要情報

73.7%

収益成長率

84.3%

EPS成長率

Healthcare Services 収益成長	20.8%
収益成長率	86.8%
将来の株主資本利益率	68.0%
アナリストカバレッジ	Low
最終更新日	08 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

ASX:ADR - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	51	10	3	3	1
6/30/2026	21	-5	-8	-8	1
6/30/2025	4	-11	-12	-12	1
6/30/2024	1	-10	-11	-11	N/A
3/31/2024	2	-9	-10	-10	N/A
12/31/2023	2	-9	-10	-10	N/A
9/30/2023	3	-9	-10	-10	N/A
6/30/2023	3	-10	-9	-9	N/A
3/31/2023	2	-10	-10	-10	N/A
12/31/2022	2	-11	-11	-11	N/A
9/30/2022	1	-10	-10	-10	N/A
6/30/2022	1	-10	-10	-10	N/A
3/31/2022	0	-11	-10	-10	N/A
12/31/2021	0	-12	-10	-10	N/A
9/30/2021	0	-13	-11	-11	N/A
6/30/2021	0	-15	-11	-11	N/A
3/31/2021	1	-15	-11	-11	N/A
12/31/2020	1	-15	-10	-10	N/A
9/30/2020	2	-13	-9	-9	N/A
6/30/2020	2	-11	-7	-7	N/A
3/31/2020	3	-10	-7	-7	N/A
12/31/2019	3	-8	-7	-6	N/A
9/30/2019	3	-10	-9	-9	N/A
6/30/2019	3	-12	-12	-12	N/A
3/31/2019	3	-12	-12	-11	N/A
12/31/2018	4	-13	-11	-11	N/A
9/30/2018	5	-11	-11	-10	N/A
6/30/2018	6	-9	-10	-10	N/A
3/31/2018	5	-11	N/A	-12	N/A
12/31/2017	4	-13	N/A	-14	N/A
9/30/2017	3	-13	N/A	-13	N/A
6/30/2017	2	-13	N/A	-12	N/A
6/30/2016	2	-6	N/A	-6	N/A
12/31/2015	2	-4	N/A	-3	N/A
3/31/2015	3	-1	N/A	0	N/A
3/31/2014	0	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ADRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ADR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ADR今後 3 年以内に収益を上げることが予想されます。

収益対市場: ADRの収益 ( 86.8% ) Australian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: ADRの収益 ( 86.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ADRの自己資本利益率は、3年後には非常に高くなると予測されています ( 68 %)。

Adherium 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Recent updates

Adherium Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released: AU$0.014 loss per share (vs AU$0.036 loss in FY 2023)

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘